Enclomiphene citrate significantly increases total and apparent free serum testosterone among men with secondary hypogonadism

After 14 days of treatment, there was a dose-dependent rise in TT levels with enclomiphene: 12.5 mg per day was associated with a level of 412 ± 194 ng/dL; 25 mg per day with 520 ± 160 ng/dL, and 50 mg per day with 589 ± 172 ng/dL, values in the normal range (298 to 1034 ng/dL). AndroGel® 1% (5.0 G), the active control, resulted in a level 473 ± 289 ng/dL, which is consistent with levels reported in the medical literature. All four treatments demonstrated statistically significant increases compared to day 1. The placebo group showed no increase in serum testosterone (mean change -1.2 ng/dL). AndroGel® 1% was also associated with a disproportionate rise in DHT relative to TT: The ratio of DHT to TT in men on AndroGel® 1% increased between day 1 and day 15 by a factor of 1.59. In comparison, men receiving placebo showed almost no change (1.07) and men on the highest dose of enclomophene had a lower ratio by a factor of 0.83. Apparent free serum testosterone levels measured by RIA demonstrated a dose-dependent rise in serum testosterone with enclomiphene whereas the placebo group did not increase.

Enclomiphene citrate (designated as Androxal™) significantly increased total and apparent free serum testosterone without increasing DHT proportionally. This new agent may represent a new oral modality for elevating testosterone in men with secondary hypogonadism.

Source: R. D. Wiehle, W. D. Garcia, M. S. Willett; FERTILITY & STERILITY

doi:10.1016/j.fertnstert.2004.07.221